Phase 2 Sclerosis Clinical Trials
122 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 122 trials
Recruiting
Phase 2
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting
Phase 2
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS)30 enrolled1 locationNCT02784210
Recruiting
Phase 2Phase 3
HEALEY ALS Platform Trial - Master Protocol
Amyotrophic Lateral Sclerosis
Merit E. Cudkowicz, MD1,500 enrolled78 locationsNCT04297683
Recruiting
Phase 1Phase 2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
Vector Y Therapeutics12 enrolled11 locationsNCT07287397
Recruiting
Phase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche182 enrolled56 locationsNCT07074886
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Atherosclerosis
Genentech, Inc.162 enrolled5 locationsNCT07448038
Recruiting
Phase 1Phase 2
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
SclerodermaSystemic Sclerosis
Cabaletta Bio12 enrolled10 locationsNCT06328777
Recruiting
Phase 2
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
ASCVDAtherosclerosis Cardiovascular DiseaseASCVD Management
Atom Therapeutics Co., Ltd200 enrolled33 locationsNCT07303777
Recruiting
Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Progressive Multiple Sclerosis
Hoffmann-La Roche360 enrolled47 locationsNCT07282574
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Systemic Sclerosis (SSc)
argenx81 enrolled74 locationsNCT06655155
Recruiting
Phase 2
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Akebia Therapeutics60 enrolled10 locationsNCT07268638
Recruiting
Phase 2
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics85 enrolled5 locationsNCT07287670
Recruiting
Phase 1Phase 2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Systemic Lupus ErythematosusLupusAutoimmune Disorders+2 more
M.D. Anderson Cancer Center47 enrolled2 locationsNCT06434363
Recruiting
Phase 1Phase 2
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 2
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
Hoffmann-La Roche12 enrolled17 locationsNCT07161258
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled69 locationsNCT06500702
Recruiting
Phase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Johns Hopkins University120 enrolled1 locationNCT07497399
Recruiting
Phase 2
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Cardiovascular DiseaseSystemic Lupus ErythematosusPremature Atherosclerosis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)45 enrolled1 locationNCT05440422
Recruiting
Phase 1Phase 2
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)250 enrolled1 locationNCT03109288
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Idiopathic Inflammatory MyopathiesSystemic Sclerosis
Nkarta, Inc.144 enrolled15 locationsNCT06733935